2-arachidonoylglycerol

2-arachidonoylglycerol is a lipid of Glycerolipids (GL) class. 2-arachidonoylglycerol is associated with abnormalities such as Atherosclerosis, Heart Diseases, Inflammatory disorder, Colitis and Peripheral Neuropathy. The involved functions are known as Immunoreactivity, inhibitors, Stimulus, Esthesia and Signal Transduction. 2-arachidonoylglycerol often locates in Back, Presynaptic Terminals, Brain region, Blood and Body tissue. The associated genes with 2-arachidonoylglycerol are ADRBK1 gene, Homologous Gene, MGLL gene, PLA2G4A gene and peptide V. The related lipids are oleoylethanolamide, Lipopolysaccharides, Promega, stearic acid and 1-stearoyl-2-arachidonoylglycerol. The related experimental models are Knock-out.

Cross Reference

Introduction

To understand associated biological information of 2-arachidonoylglycerol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 2-arachidonoylglycerol?

2-arachidonoylglycerol is suspected in Atherosclerosis, Heart Diseases, Sweet's Syndrome, Colitis, Dehydration, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2-arachidonoylglycerol

MeSH term MeSH ID Detail
Hepatic Encephalopathy D006501 9 associated lipids
Weight Gain D015430 101 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Glioma D005910 112 associated lipids
Obesity D009765 29 associated lipids
Alzheimer Disease D000544 76 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Nervous System Diseases D009422 37 associated lipids
Brain Edema D001929 20 associated lipids
Starvation D013217 47 associated lipids
Per page 10 20 50 100 | Total 51

PubChem Associated disorders and diseases

What pathways are associated with 2-arachidonoylglycerol

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with 2-arachidonoylglycerol?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 2-arachidonoylglycerol?

Knock-out

Knock-out are used in the study 'Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.' (Walentiny DM et al., 2015), Knock-out are used in the study 'Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).' (Navia-Paldanius D et al., 2012) and Knock-out are used in the study 'Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.' (Viader A et al., 2015).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with 2-arachidonoylglycerol

Download all related citations
Per page 10 20 50 100 | Total 1060
Authors Title Published Journal PubMed Link
Niki M et al. Modulation of sweet taste sensitivities by endogenous leptin and endocannabinoids in mice. 2015 J. Physiol. (Lond.) pmid:25728242
Frazier CJ Key questions of endocannabinoid signalling in the CNS: which, where and when? 2011 J. Physiol. (Lond.) pmid:22001725
Szabo B et al. Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol. 2006 J. Physiol. (Lond.) pmid:16973696
Zhong P et al. Genetic deletion of monoacylglycerol lipase alters endocannabinoid-mediated retrograde synaptic depression in the cerebellum. 2011 J. Physiol. (Lond.) pmid:21911610
Xu JY et al. Long-lasting potentiation of hippocampal synaptic transmission by direct cortical input is mediated via endocannabinoids. 2012 J. Physiol. (Lond.) pmid:22411015
Hofmann ME et al. Cannabinoid receptor agonists potentiate action potential-independent release of GABA in the dentate gyrus through a CB1 receptor-independent mechanism. 2011 J. Physiol. (Lond.) pmid:21646412
Hashimotodani Y et al. Acute inhibition of diacylglycerol lipase blocks endocannabinoid-mediated retrograde signalling: evidence for on-demand biosynthesis of 2-arachidonoylglycerol. 2013 J. Physiol. (Lond.) pmid:23858009
Lindgren CA et al. Cyclooxygenase-2, prostaglandin E2 glycerol ester and nitric oxide are involved in muscarine-induced presynaptic enhancement at the vertebrate neuromuscular junction. 2013 J. Physiol. (Lond.) pmid:23818695
Frazier CJ Preformed vs. on-demand: molecular economics of endocannabinoid signalling. 2013 J. Physiol. (Lond.) pmid:24085490
Straiker A and Mackie K Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. 2005 J. Physiol. (Lond.) pmid:16179366
Sang N et al. PGE2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons. 2006 J. Physiol. (Lond.) pmid:16484297
Straiker A and Mackie K Metabotropic suppression of excitation in murine autaptic hippocampal neurons. 2007 J. Physiol. (Lond.) pmid:17110416
Yoshino H et al. Postsynaptic diacylglycerol lipase mediates retrograde endocannabinoid suppression of inhibition in mouse prefrontal cortex. 2011 J. Physiol. (Lond.) pmid:21807615
Di S et al. Activity-dependent release and actions of endocannabinoids in the rat hypothalamic supraoptic nucleus. 2005 J. Physiol. (Lond.) pmid:16239276
Alger BE Endocannabinoids at the synapse a decade after the dies mirabilis (29 March 2001): what we still do not know. 2012 J. Physiol. (Lond.) pmid:22289914
Fino E et al. Distinct coincidence detectors govern the corticostriatal spike timing-dependent plasticity. 2010 J. Physiol. (Lond.) pmid:20603333
Haj-Dahmane S and Shen RY Regulation of plasticity of glutamate synapses by endocannabinoids and the cyclic-AMP/protein kinase A pathway in midbrain dopamine neurons. 2010 J. Physiol. (Lond.) pmid:20498231
Shimizu T et al. Stimulatory and inhibitory roles of brain 2-arachidonoylglycerol in bombesin-induced central activation of adrenomedullary outflow in rats. 2013 J. Pharmacol. Sci. pmid:23386378
Sugiura T et al. New perspectives in the studies on endocannabinoid and cannabis: 2-arachidonoylglycerol as a possible novel mediator of inflammation. 2004 J. Pharmacol. Sci. pmid:15599096
Darmani NA The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids. 2002 J. Pharmacol. Exp. Ther. pmid:11752094
Kinsey SG et al. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. 2009 J. Pharmacol. Exp. Ther. pmid:19502530
Wallace MJ et al. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. 2003 J. Pharmacol. Exp. Ther. pmid:12954810
Lichtman AH et al. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. 2002 J. Pharmacol. Exp. Ther. pmid:12065702
Patel S et al. Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity. 2003 J. Pharmacol. Exp. Ther. pmid:12808005
McDougle DR et al. Endocannabinoids anandamide and 2-arachidonoylglycerol are substrates for human CYP2J2 epoxygenase. 2014 J. Pharmacol. Exp. Ther. pmid:25277139
Caprioli A et al. The novel reversible fatty acid amide hydrolase inhibitor ST4070 increases endocannabinoid brain levels and counteracts neuropathic pain in different animal models. 2012 J. Pharmacol. Exp. Ther. pmid:22514334
Kinsey SG et al. Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects. 2013 J. Pharmacol. Exp. Ther. pmid:23412396
Ritter JK et al. Production and actions of the anandamide metabolite prostamide E2 in the renal medulla. 2012 J. Pharmacol. Exp. Ther. pmid:22685343
Vannacci A et al. The endocannabinoid 2-arachidonylglycerol decreases the immunological activation of Guinea pig mast cells: involvement of nitric oxide and eicosanoids. 2004 J. Pharmacol. Exp. Ther. pmid:15187170
Lee M et al. Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes. 1995 J. Pharmacol. Exp. Ther. pmid:7473135
Shoemaker JL et al. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. 2005 J. Pharmacol. Exp. Ther. pmid:16081674
Martin BR et al. Cannabinoid properties of methylfluorophosphonate analogs. 2000 J. Pharmacol. Exp. Ther. pmid:10945879
Shoemaker JL et al. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. 2005 J. Pharmacol. Exp. Ther. pmid:15901805
Pan B et al. Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) Enhances retrograde endocannabinoid signaling. 2009 J. Pharmacol. Exp. Ther. pmid:19666749
Hillard CJ Endocannabinoids and vascular function. 2000 J. Pharmacol. Exp. Ther. pmid:10871291
Aaltonen N et al. In Vivo Characterization of the Ultrapotent Monoacylglycerol Lipase Inhibitor {4-[bis-(benzo[d][1,3]dioxol-5-yl)methyl]-piperidin-1-yl}(1H-1,2,4-triazol-1-yl)methanone (JJKK-048). 2016 J. Pharmacol. Exp. Ther. pmid:27451409
Wilkerson JL et al. The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model. 2016 J. Pharmacol. Exp. Ther. pmid:26791602
Leonard MZ et al. Cannabinoid CB Discrimination: Effects of Endocannabinoids and Catabolic Enzyme Inhibitors. 2017 J. Pharmacol. Exp. Ther. pmid:28947487
Raman P et al. 15-Deoxy-Δ¹²,¹⁴-prostaglandin J₂-glycerol, a putative metabolite of 2-arachidonyl glycerol and a peroxisome proliferator-activated receptor γ ligand, modulates nuclear factor of activated T cells. 2012 J. Pharmacol. Exp. Ther. pmid:22700433
Giuffrida A et al. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. 2001 J. Pharmacol. Exp. Ther. pmid:11408519
Burston JJ et al. N-arachidonyl maleimide potentiates the pharmacological and biochemical effects of the endocannabinoid 2-arachidonylglycerol through inhibition of monoacylglycerol lipase. 2008 J. Pharmacol. Exp. Ther. pmid:18682568
Chiba T et al. A synthetic cannabinoid, CP55940, inhibits lipopolysaccharide-induced cytokine mRNA expression in a cannabinoid receptor-independent mechanism in rat cerebellar granule cells. 2011 J. Pharm. Pharmacol. pmid:21492165
Duclos RI et al. A methodology for radiolabeling of the endocannabinoid 2-arachidonoylglycerol (2-AG). 2011 J. Org. Chem. pmid:21370840
Midtbø LK et al. Intake of farmed Atlantic salmon fed soybean oil increases hepatic levels of arachidonic acid-derived oxylipins and ceramides in mice. 2015 J. Nutr. Biochem. pmid:25776459
Hutchins-Wiese HL et al. Hind limb suspension and long-chain omega-3 PUFA increase mRNA endocannabinoid system levels in skeletal muscle. 2012 J. Nutr. Biochem. pmid:22051448
Kim J and Watkins BA Cannabinoid receptor antagonists and fatty acids alter endocannabinoid system gene expression and COX activity. 2014 J. Nutr. Biochem. pmid:24854955
Liisberg U et al. Intake of a Western diet containing cod instead of pork alters fatty acid composition in tissue phospholipids and attenuates obesity and hepatic lipid accumulation in mice. 2016 J. Nutr. Biochem. pmid:27155918
Mennella I et al. Food Liking Enhances the Plasma Response of 2-Arachidonoylglycerol and of Pancreatic Polypeptide upon Modified Sham Feeding in Humans. 2015 J. Nutr. pmid:26180248
Batetta B et al. Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. 2009 J. Nutr. pmid:19549757
Katz PS et al. Endocannabinoid degradation inhibition improves neurobehavioral function, blood-brain barrier integrity, and neuroinflammation following mild traumatic brain injury. 2015 J. Neurotrauma pmid:25166905